The antiviral activities of heparin precursor fractions, F1 to F4, were evaluated by measuring cell death prevention by assaying adenylate kinase (AK) activity released by damaged cells (Figure 2A), and their impact on viral replication was assessed by plaque-forming units (PFU) 6 days after infection (Figure 2B). The gene discussed is ADK; the disease is infection.